TrialThe Lancet. Oncology2020

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

Daniel P Petrylak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.